Clonal evolution in aplastic anemia | Aplastic Anemia and MDS International Foundation

Clonal evolution in aplastic anemia

Journal Title: 
Hematology Am Soc Hematol Educ Program
Author(s): 
Afable MG 2nd, Tiu RV, Maciejewski JP
Primary Author: 
Afable MG 2nd
Original Publication Date: 
Thursday, December 1, 2011

Current immunosuppressive treatment (IST) induces remissions in 50%-70% of patients with aplastic anemia (AA) and result in excellent long-term survival. In recent years, the survival of refractory patients has also improved. Apart from relapse and refractoriness to IST, evolution of clonal diseases, including paroxysmal nocturnal hemoglobinuria and myelodysplastic syndrome (MDS), are the most serious long-term complications and constitute a strong argument for definitive therapy with BM transplantation if possible. Consequently, the detection of diagnostic chromosomal abnormalities (mostly monosomy 7) is of great clinical importance. Newer whole-genome scanning technologies such as single nucleotide polymorphism (SNP) array-based karyotyping may be a helpful diagnostic test for the detection of chromosomal defects in AA due to its precision/resolution and lack of reliance on cell division.

Bone Marrow Diseases: